CD44 and breast carcinoma: For instance, a clinical pilot study shows that doxycycline, a Food and Drug Administration (FDA)-approved antibiotic, effectively reduces cancer stem cells, with a decrease of stem cell markers CD44 and ALDH1 expression, in early breast cancer patients [16].